These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

783 related articles for article (PubMed ID: 29215183)

  • 1. Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey.
    Potenza MC; Peris K; Berardesca E; Bianchi L; Richetta A; Bernardini N; De Simone C; Teoli M; Zangrilli A; D'epiro S; Orsini D; Narcisi A; Chimenti S; Costanzo A
    Dermatol Ther; 2018 Jan; 31(1):. PubMed ID: 29215183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical predictors of nonresponse to anti-TNF-α agents in psoriatic patients: A retrospective study.
    De Simone C; Caldarola G; Maiorino A; Tassone F; Campana I; Sollena P; Peris K
    Dermatol Ther; 2016 Sep; 29(5):372-376. PubMed ID: 27146358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
    Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
    Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elderly psoriatic arthritis patients on TNF-α blockers: results of an Italian multicenter study on minimal disease activity and drug discontinuation rate.
    Costa L; Lubrano E; Ramonda R; Chimenti MS; Vezzù M; Perrotta FM; Del Puente A; Peluso R; Bottiglieri P; Lorenzin M; Sunzini F; Darda MA; Fiocco U; Perricone R; Punzi L; Scarpa R; Caso F
    Clin Rheumatol; 2017 Aug; 36(8):1797-1802. PubMed ID: 28589323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TNF-α in a molecularly targeted therapy of psoriasis and psoriatic arthritis.
    Wcisło-Dziadecka D; Zbiciak-Nylec M; Brzezińska-Wcisło L; Mazurek U
    Postgrad Med J; 2016 Mar; 92(1085):172-8. PubMed ID: 26719452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study.
    Saougou I; Markatseli TE; Papagoras C; Voulgari PV; Alamanos Y; Drosos AA
    Semin Arthritis Rheum; 2011 Apr; 40(5):398-406. PubMed ID: 20843542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis.
    Cawson MR; Mitchell SA; Knight C; Wildey H; Spurden D; Bird A; Orme ME
    BMC Musculoskelet Disord; 2014 Jan; 15():26. PubMed ID: 24444034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of Hospitalization for Serious Infection After Initiation of Ustekinumab or Other Biologics in Patients With Psoriasis or Psoriatic Arthritis.
    Jin Y; Lee H; Lee MP; Landon JE; Merola JF; Desai RJ; Kim SC
    Arthritis Care Res (Hoboken); 2022 Nov; 74(11):1792-1805. PubMed ID: 33973371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis.
    Sauer BC; Teng CC; He T; Leng J; Lu CC; Walsh JA; Shah N; Harrison DJ; Tang DH; Cannon GW
    J Med Econ; 2016; 19(1):34-43. PubMed ID: 26337538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-TNF-α Drugs Differently Affect the TNFα-sTNFR System and Monocyte Subsets in Patients with Psoriasis.
    Gibellini L; De Biasi S; Bianchini E; Bartolomeo R; Fabiano A; Manfredini M; Ferrari F; Albertini G; Trenti T; Nasi M; Pinti M; Iannone A; Salvarani C; Cossarizza A; Pellacani G
    PLoS One; 2016; 11(12):e0167757. PubMed ID: 27936119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study.
    Talamonti M; Galluzzo M; Bernardini N; Caldarola G; Persechino S; Cantoresi F; Egan CG; Potenza C; Peris K; Bianchi L
    J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1737-1744. PubMed ID: 29776016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA.
    Iannone F; Lopriore S; Bucci R; Scioscia C; Anelli MG; Notarnicola A; Lapadula G
    Scand J Rheumatol; 2015 May; 44(3):192-9. PubMed ID: 25564882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis.
    Gisondi P; Bellinato F; Targher G; Idolazzi L; Girolomoni G
    Ann Rheum Dis; 2022 Jan; 81(1):68-73. PubMed ID: 34144965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and drug survival of TNF-inhibitors in the treatment of psoriatic arthritis: A prospective cohort study.
    Aaltonen K; Heinonen A; Joensuu J; Parmanne P; Karjalainen A; Varjolahti-Lehtinen T; Uutela T; Puurtinen-Vilkki M; Arstila L; Blom M; Sokka T; Nordström D
    Semin Arthritis Rheum; 2017 Jun; 46(6):732-739. PubMed ID: 28010883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis.
    Acosta Felquer ML; LoGiudice L; Galimberti ML; Rosa J; Mazzuoccolo L; Soriano ER
    Ann Rheum Dis; 2022 Jan; 81(1):74-79. PubMed ID: 34281904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paradoxical onset of psoriatic arthritis during treatment with biologic agents for plaque psoriasis: a combined dermatology and rheumatology clinical study.
    Napolitano M; Balato N; Caso F; Costa L; Megna M; Cirillo T; Balato A; Scarpa R
    Clin Exp Rheumatol; 2017; 35(1):137-140. PubMed ID: 27749221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis.
    Kirson NY; Rao S; Birnbaum HG; Kantor E; Wei RS; Cifaldi M
    J Med Econ; 2013; 16(4):479-89. PubMed ID: 23339434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psoriatic arthritis treated by anti-TNFs: a monocentric trial of 102 cases in Auvergne, France.
    Soubrier M; Pereira B; Frayssac T; Abdi D; Couderc M; Daron C; Malochet-Guinamand S; Mathieu S; Tatar Z; Tournadre A; Dubost JJ
    Clin Exp Rheumatol; 2016; 34(6):1059-1064. PubMed ID: 27607233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis.
    Carrera CG; Dapavo P; Malagoli P; Naldi L; Arancio L; Gaiani F; Egan CG; Di Mercurio M; Cattaneo A
    J Dermatolog Treat; 2018 Aug; 29(5):481-486. PubMed ID: 29058948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival and Effectiveness of Tumour Necrosis Factor-alpha Inhibitors in the Treatment of Plaque Psoriasis under Daily Life Conditions: Report from the Psoriasis Registry Austria.
    Inzinger M; Wippel-Slupetzky K; Weger W; Richter L; Mlynek A; Fleischander B; Scheurecker C; Sandor N; Mairhofer D; Sator PG; Moser-Oberthaler S; Häring N; Viznerova P; Painsi C; Tanew A; Ponholzer P; Tatarski R; Brenner W; Stingl G; Salmhofer W; Rappersberger K; Klein G; Saxinger W; Auböck J; Kölli C; Trautinger F; Steiner A; Ratzinger G; Strohal R; Riedl E; Lange-Asschenfeldt B; Pehamberger H; Volc-Platzer B; Selhofer S; Legat FJ; Müllegger R; Reider N; Schmuth M; Hintner H; Hofer A; Gruber-Wackernagel A; Aberer W; Quehenberger F; Wolf P
    Acta Derm Venereol; 2016 Feb; 96(2):207-12. PubMed ID: 26271044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.